AQR Capital Management
ADCT icon

AQR Capital Management’s ADC Therapeutics ADCT Stock Holding History

AQR Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$891K Buy
237,637
+31,061
+15% +$122K ﹤0.01% 2831
2025
Q4 		$729K Buy
206,576
+61,324
+42% +$249K ﹤0.01% 2718
2025
Q3 		$581K Buy
145,252
+4,672
+3% +$14.7K ﹤0.01% 2734
2025
Q2 		$377K Sell
140,580
-60,590
-30% -$127K ﹤0.01% 2753
2025
Q1 		$284K Buy
201,170
+161,808
+411% +$275K ﹤0.01% 2715
2024
Q4 		$78.3K Buy
39,362
+17,255
+78% +$45.2K ﹤0.01% 2785
2024
Q3 		$69.6K Buy
+22,107
New +$69.7K ﹤0.01% 2686

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management's ADCT Position: Q1 2026 in Review

AQR Capital Management increased its ADC Therapeutics (ADCT) stake by 15% in Q1 2026, buying an estimated $122K and bringing the position to 237,637 shares worth $891K. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

AQR Capital Management first reported a position in ADCT in Q3 2024 and has held it in 7 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • AQR Capital Management held 237,637 shares of ADC Therapeutics worth $891K as of Q1 2026.
  • AQR Capital Management bought 31,061 ADC Therapeutics shares in Q1 2026, an estimated $122K.
  • ADC Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2831 holding.
  • AQR Capital Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.